Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trials to be complete by 2028!
How long has this site been up?
http://www.anavexaustralia.com
Why haven't we received any FDA information?
I used to post quite a bit. There has been very little new information and most of the posts are re-hash or speculation from both sides. I get entertainment from some of the posts, but I invested to make money. As investors we should not have to keep guessing what is going on, or search for hidden eggs. I did invest in the science, but have gotten bored over the years. I was expecting more from the genomic research, but hey, maybe there are more hidden eggs.
There were actually many pre-screening applications filled out 11 months ago. Where did his information go if Anavex was not collecting it? Who is the clinical research organization? Where are the trial sites? This was an at home study, where are comments from the parents 11 months later? Why start this prescreening for a 12 week trial if the FDA wasn't on board? Why haven't investors received more information on the status of the IND from nearly a year ago? Just seems kind of odd that there is little to no information in the US from the FDA on any of these trials.
https://www.rettsyndrome.org/research/clinical-trials
Pharmacological Interventional Clinical Trials
Updated 3/5/18
ANAVEX 2-73 pre-qualifying online survey http://www.rettsyndrometrial.com
https://www.rettsyndrome.org/file/andrea-files/anavexflyer.pdf
Searched through clinicaltrials.gov but did not see anything. Terms and conditions state: THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY. Access to and use of this web site is subject to the above terms and conditions.
Maybe thy his was a prestaged website, it has copyright from late 2017.
TOCRIS?
Discontinued Product
ANAVEX 2-73 (Cat. No. 5058) has been withdrawn from sale for commercial reasons.
Who is manufacturing A2-73 for trials?
Why not wait for P2b/P3 to complete? Then you would have more conclusive scientific information to support your case. Should only be about 2 years away...
Why does everyone always talk about Anavex 2-73 as a sigma 1 receptor agonist only? It is a mixed ligand for muscarinic receptors also. It works well as as n antimuscarinic compound. There is research data on various types of these compounds as well, and the combination of a sigma 1 agonist seems to make this compound tolerable. This is a novel compound, and not just any sigma 1 receptor agonist.
It's time to get the trials started.
Been waiting a while for trials to get underway. With so many options it would be nice to see commitment to at least one direction. There have been so many preclinical trials that have had promising results. Let's get this show on the road. I'd like to see epilepsy gain traction again.
Those that claim this drug won't work are no better than those that claim that it does. Until trials are complete it is an odds game. As trials progress, the market generally gives more value for various reasons.
Like Eisai? Makers of ______?
Thanks, makes more sense.
Excercise and expiration dates are 9/22/2016...
Warrants?
Really...
Let me help you out...
https://www.sec.gov/investor/pubs/regsho.htm
Do all failures to deliver reflect improper activity? After adoption of Rule 204, why are there still failures to deliver?
A failure to deliver occurs when a broker-dealer fails to deliver securities to the party on the other side of the transaction on the settlement date. There are many justifiable reasons why broker-dealers do not or cannot deliver securities on the settlement date. A broker-dealer may experience a problem that is either unanticipated or is out of its control, such as (1) delays in customers delivering their shares to a broker-dealer, (2) the inability to obtain borrowed shares in time for settlement, (3) issues related to the physical transfer of securities, or (4) the failure of a broker-dealer to receive shares it had purchased to fulfill its delivery obligations. Failures to deliver can result from both long and short sales.
Failures to deliver may result from either a short or a long sale. There may be legitimate reasons for a failure to deliver. For example, human or mechanical errors or processing delays can result from transferring securities in physical certificate rather than book-entry form, thus causing a failure to deliver on a long sale within the normal three-day settlement period. A fail may also result from “naked” short selling. For example, market makers who sell short thinly traded, illiquid stock in response to customer demand may encounter difficulty in obtaining securities when the time for delivery arrives.
You can argue with the SEC, these are there words not mine.
Do you work for LPC?
Hmm, SEC says otherwise...
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, and are not evidence of abusive short selling or “naked” short selling. For more information on short selling and fails-to-deliver, see http://www.sec.gov/investor/pubs/regsho.htm, http://www.sec.gov/divisions/marketreg/mrfaqregsho1204.htm, and http://www.sec.gov/rules/final/34-50103.htm.
So I appreciate being called "WRONG".
Your missing a lot of trades that the sec has as fails to deliver...
E.g. 20151027|032797300|AVXLD|96116|ANAVEX LIFE SCIENCES CORP|8.37
https://www.sec.gov/foia/docs/failsdata-archive.htm
These do not only represent sales though and could be long positions that failed to pay.
There is a lot going on with this little company. I imagine someone is wondering if LPC is involved. Short at those highs as shelf was not available, then wait for the company to ask for money and cover at half the price.
Nevada Anti-Takeover Law and Charter and Bylaws Provisions
Nevada Revised Statutes sections 78.378 to 78.3793 provide state regulation over the acquisition of a controlling interest in certain Nevada corporations unless the articles of incorporation or bylaws of the corporation provide that the provisions of these sections do not apply. The statute creates a number of restrictions on the ability of a person or entity to acquire control of a Nevada company by setting down certain rules of conduct and voting restrictions in any acquisition attempt, among other things. The statute is limited to corporations that are organized in the state of Nevada and that have 200 or more shareholders, at least 100 of whom are shareholders of record and residents of the State of Nevada; and do business in the State of Nevada directly or through an affiliated corporation. Because of these conditions, the statute does not apply to our Company.
There are no provisions in our articles of incorporation or our bylaws that would delay, defer or prevent a change in control of our Company.
A 4 year moving average? Just looking back at what has happened in that timeline, that is a little concerning. LPC wreaked havok on this stock a couple of years ago with the $10M dilution,and to see us at the 200 weekly ma is concerning. Pull the cart back 2 years and see where the 200 weekly ma was...
Where are you getting 2.80 for 200ma?
George, what does this have to do with Anavex? The four drugs are: Leukine, Sativex, Senicapoc and Longeveron stem cells. Would be nice to hear of a little funding for Anavex, but I don't see how that is it.
To clarify:
The purchase price per share for each such Regular Purchase will be equal to the lower of:
• the lowest sale price for our Common Stock on the purchase date of such shares; or
• the arithmetic average of the three lowest closing sale prices for our Common Stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date of such shares.
They Then own the stock and can sell at any time they wish. I believe there is also a cap of 10% of the outstanding shares that they can own at any one time, but would have to check. This may become a good trading stock...
They won't "dump" the shares, they can't make money that way. They buy the shares at market value according to the agreement. If they just "dumped" the shares they would lose a lot of money. With the small up front amount of shares, they couldn't offset the loss.
Probably celebrating...
Have you been drinking?
Regulatory Approval- Ethics Committee Approves trial of Anavex 2-73 and AnavexPLUS
Anavex2-73 Trial NCT02244541
ClinicalTrials.gov processed this record on September 25, 2014
http://www.clinicaltrials.gov/ct2/show/study/NCT02244541?term=anavex&rank=1#contacts
Trial to start in November.
Primary completion date: September 2015
Study completion: February 2016
Primary Outcome Measures:
•To determine maximum tolerated dose of Anavex2-73. [ Time Frame: 36 Days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
•PK sampling- blood test results [ Time Frame: First part (PART A), first period (hours): 1, 48, 264; second period (hours): 1, 72, 264; extension period (PART B): Week 1, 12 and 26. ] [ Designated as safety issue: No ]
•Mini-mental state examination score (MMSE) [ Time Frame: Baseline, and during the extension period at Week 1, 12 and 26. ] [ Designated as safety issue: No ]
•Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory) [ Time Frame: Baseline, and during the extension period at Week 1, 12 and 26 ] [ Designated as safety issue: No ]
•Cogstate Brief Battery (CBB) Score and International Shopping List Task (ISLT) Score [ Time Frame: At baseline, Day 1, 2, 6, 9, 12 of Period 1 and Day 1, 2, 6, 9, 12 of Period 2 and during the extension period at Week 12 and 26. ] [ Designated as safety issue: No ]
•Electroencephalographic activity, including event-related potentials (EEG/ERP) [ Time Frame: baseline, Day 1, 5, 11 of Period 1 and Day 1, 5, 11 of Period 2 and, Week 12 and 26 of the extension period ] [ Designated as safety issue: No ]
•Hamilton Psychiatric Rating Scale for Depression (HAM-D) Score [ Time Frame: Baseline at Period 1 ] [ Designated as safety issue: No ]
•Rosen Modified Hachinski Ischemic Score (RM/HIS10) [ Time Frame: Baseline at period 1 ] [ Designated as safety issue: No ]
Hey Tom,
I'm hoping it is just a scare tactic to get people to sell their shares, otherwise there should have been news by now on this insider trading.
I am guessing it's a scare tactic due to low volumes, low price and no news.
Friday we should find out about ethics committe approval of trial or not. Of course we have the end of a quarter to face with more losses as well.